[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-339023-105":59,"doc-detail-339023-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","sindbis-virus-vaccine-platform-a-promising-oncolytic-virus-mediated-approach-for-ovarian-cancer-treatment","Sindbis Virus Vaccine Platform - A Promising Oncolytic Virus-Mediated Approach for Ovarian Cancer Treatment","","Reviewing Sindbis virus vaccine platform for ovarian cancer immunotherapy, the article explains why the disease remains highly lethal despite aggressive, limited standard treatments that lead to recurrence and 50–60% mortality within five years. It details the molecular biology of Sindbis virus and the in vivo mechanisms of armed oncolytic Sindbis vectors to target ovarian cancer cells. Preclinical studies and future perspectives are synthesized, alongside insights from other oncolytic viruses.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/sindbis-virus-vaccine-platform-a-promising-oncolytic-virus-mediated-approach-for-ovarian-cancer-treatment/339023/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/sindbis-virus-vaccine-platform-a-promising-oncolytic-virus-mediated-approach-for-ovarian-cancer-treatment/339023.png","ImageObject",300,407,{"name":92,"@type":93},"Finn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main focus of the Sindbis virus vaccine platform review?","Question",{"text":112,"@type":113},"The review focuses on a novel Sindbis virus vaccine platform as a potential immunotherapy for ovarian cancer, covering biology, mechanisms, and evidence from preclinical studies.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why is ovarian cancer considered difficult to treat with current options?",{"text":117,"@type":113},"Standard approaches are aggressive yet limited, with high rates of recurrence and substantial mortality within five years.",{"name":119,"@type":110,"acceptedAnswer":120},"What obstacles does the ovarian cancer tumor microenvironment create for immunotherapy?",{"text":121,"@type":113},"The ovarian cancer tumor microenvironment enables efficient metastasis and impairs immune surveillance, reducing the effectiveness of immunotherapeutic strategies.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},339023,1790192904,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":31,"preview_page_count":19,"preview_urls":144},34359740700684,"https://ap-avatar.wpscdn.com/avatar/1f400023980c374ae676?_k=1777273430885731487","Review  \nSindbis Virus Vaccine Platform: A Promising Oncolytic Virus-Mediated Approach for Ovarian Cancer Treatment  \nChristine Pampeno 1, Silvana Opp 2, Alicia Hurtado 1 and Daniel Meruelo 1, *  \nCitation: Pampeno, C.; Opp, S.; Hurtado, A.; Meruelo, D. Sindbis Virus Vaccine Platform: A Promising Oncolytic Virus-Mediated Approach for Ovarian Cancer Treatment. Int. J. Mol. Sci. 2024, 25, 2925. [https://](https://)[ ](https://)[doi.org/10.3390/ijms25052925](doi.org/10.3390/ijms25052925)  \nAcademic Editor: Carmela Ricciardelli  \nReceived: 13 December 2023  \nRevised: 30 January 2024  \nAccepted: 28 February 2024  \nPublished: 2 March 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Pathology, NYU Grossman School of Medicine, New York University, New York, NY 10016, USA  \n2 BioNTech, Cambridge, MA 02139, USA  \n* Correspondence: [daniel.meruelo@nyulangone.org](daniel.meruelo@nyulangone.org); Tel.: +1-212-263-5599; Fax: +1-212-263-8211 Abstract: This review article provides a comprehensive overview of a novel Sindbis virus vaccine platform as potential immunotherapy for ovarian cancer patients. Ovarian cancer is the most lethal of all gynecological malignancies. The majority of high-grade serous ovarian cancer (HGSOC) patients are diagnosed with advanced disease. Current treatment options are very aggressive and limited, resulting in tumor recurrences and 50–60% patient mortality within 5 years. The unique properties of armed oncolytic Sindbis virus vectors (SV) in vivo have garnered significant interest in recent years to potently target and treat ovarian cancer. We discuss the molecular biology of Sindbis virus, its mechanisms of action against ovarian cancer cells, preclinical in vivo studies, and future perspectives. The potential of Sindbis virus-based therapies for ovarian cancer treatment holds great promise and warrants further investigation. Investigations using other oncolytic viruses in preclinical studies and clinical trials are also presented.  \nKeywords: Sindbis virus; oncolytic virus; ovarian cancer; immunotherapy  \n1. Introduction  \n1.1. Ovarian Cancer as a Significant Health Concern  \nOvarian cancer is one of the most common and lethal types of gynecological cancers with an overall survival rate of 50 percent that has not changed significantly for several decades [1–3] . Although it can occur at any age, it primarily affects women who have gone through menopause. The estimated rate of new cases and death in 2023 are 19,710 and 13,720, respectively [4] . Due to the absence of noticeable symptoms, ovarian cancer often goes undetected in its early stages and hence is referred to as the “silent killer” [5–8] . Asthe disease progresses, symptoms include abdominal bloating or swelling, difficulty eating or feeling full quickly, pelvic pain and fatigue. These symptoms can be indicative of other conditions as well, which makes early detection and accurate diagnosis challenging. As a result, patients are frequently diagnosed at an advanced stage when tumors have already spread beyond the ovaries. Thus, metastasis presents the greatest therapeutic challenge, restricting successful treatment of patients and dramatically reducing the overall survival rate [9,10].  \nThere are different types of ovarian cancer, with epithelial ovarian cancer being the most common form, accounting for about 90% of cases [9,11–15] . Highly aggressive highgrade serous ovarian carcinoma (HGSOC) is the most common epithelial subtype with a tendency to develop early chemotherapy resistance. HGSOC presents with various molecular abnormalities, especially TP53 mutations observed in the majority of tumors [16] . Other less common ","cbCaie1cXBsDdAYV","https://ap.wps.com/l/cbCaie1cXBsDdAYV","pdf",1449689,"English","# Abstract\n# Introduction\n## Ovarian Cancer as a Significant Health Concern\n## Current Treatment Challenges and Limitations\n## HGSOC Tumor Microenvironment Presents Obstacles to Treatment","[{\"question\":\"What is the main focus of the Sindbis virus vaccine platform review?\",\"answer\":\"The review focuses on a novel Sindbis virus vaccine platform as a potential immunotherapy for ovarian cancer, covering biology, mechanisms, and evidence from preclinical studies.\"},{\"question\":\"Why is ovarian cancer considered difficult to treat with current options?\",\"answer\":\"Standard approaches are aggressive yet limited, with high rates of recurrence and substantial mortality within five years.\"},{\"question\":\"What obstacles does the ovarian cancer tumor microenvironment create for immunotherapy?\",\"answer\":\"The ovarian cancer tumor microenvironment enables efficient metastasis and impairs immune surveillance, reducing the effectiveness of immunotherapeutic strategies.\"}]","Sindbis Virus Vaccine Platform - A Promising Oncolytic Virus-Mediated Approach for Ovarian Cancer Treatment | PDF",1790027380,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1c75b10a628386fa3488b563deb48c39.webp",983,1390,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0235f3d1b641f678842babe5e86b4749.webp",982,1388,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d73c0c313c109dc9b4f21c4e9529b9cd.webp",981,1387,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/739ed076b20e38010db7cbaaabdabb8c.webp",980,1385]